# A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Source: https://onco.cc/trials/nct06208410/  
OnCo record `nct06208410` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JS105, Fulvestrant, Dalpiciclib, Toripalimab, Pyrotinib and Capecitabine in advanced solid tumours, run by Risen (Suzhou) Pharma Tech Co., Ltd., now recruiting.

## Summary

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06208410 by Risen (Suzhou) Pharma Tech Co., Ltd., with 306 participants planned, started 2024-01-11 and due to reach its primary completion in 2027-02-26. Interventions recorded: JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets, Toripalimab Injection, Paclitaxel for Injection (Albumin Bound) and Fluzoparib Capsules.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06208410
- Phase: 1/2
- Setting: A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.
- Enrolled: 306

## Sources

- ClinicalTrials.gov NCT06208410: https://clinicaltrials.gov/study/NCT06208410

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Dalpiciclib](https://onco.cc/drugs/dalpiciclib/), [Fluzoparib](https://onco.cc/drugs/fluzoparib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [JS105](https://onco.cc/drugs/js105/), [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)

---
JSON: https://onco.cc/api/v1/entities/nct06208410.json